Therapeutic Response to Psychedelic Therapy – Who, What, Why & How?

Psilocybin and MDMA therapy are now in Phase 3 trials for Treatment Resistant Depression and Post Traumatic Stress Disorder, respectively. Meanwhile, other psychedelics are in earlier phases of development. Blinding is largely impossible in such trials, and psychological support is given as standard. A complex interplay between drug and non-drug effects is likely to mediate outcome. Identifying this interplay may allow the optimization of the process of treatment by identifying key factors of "set" and "setting", informing models of therapy and how dosing session environments are set up. This collection focuses on non-drug factors that may serve as predictors and mediators of response to treatment with psychedelic therapy, including psilocybin, MDMA and related compounds.